US researchers have uncovered the role of Plasmodium falciparum — a parasitic protozoan that causes malaria — in the ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

Mortality risk among patients with Sjögren’s disease is elevated as much as 70% vs. the general population, primarily due to ...

Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...

Kennewick's beloved children's bookstore becomes first NuMarket campaign in the Tri-Cities ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

The risk of developing blood cancer increases with age. The finding that a molecule from gut bacteria plays a part points to ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...

A ready-made version of a cutting-edge cancer immunotherapy can effectively defeat blood cancers, a new study says.